---
title: "股東警報：Levi & Korsinsky, LLP 通知投資者已對購買 MacroGenics, Inc.證券所遭受的損失提起訴訟，並設定了2024年9月24日的首席原告截止日期"
description: "一家針對 MacroGenics, Inc.提起的集體訴訟指控其對藥物安全數據進行了誤導性陳述。在曝光該藥物比先前所述更危險後，該公司股價下跌了 77.4%。投資者需在 2024 年 9 月 24 日之前提出請求成為首席原告"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/209981727.md"
published_at: "2024-07-27T00:40:37.000Z"
---

# 股東警報：Levi & Korsinsky, LLP 通知投資者已對購買 MacroGenics, Inc.證券所遭受的損失提起訴訟，並設定了2024年9月24日的首席原告截止日期

> 一家針對 MacroGenics, Inc.提起的集體訴訟指控其對藥物安全數據進行了誤導性陳述。在曝光該藥物比先前所述更危險後，該公司股價下跌了 77.4%。投資者需在 2024 年 9 月 24 日之前提出請求成為首席原告

NEW YORK, July 26, 2024 ( GLOBE NEWSWIRE ) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of MacroGenics, Inc. ( "MacroGenics" or the "Company" ) MGNX between March 7, 2024 to May 9, 2024, both ...

### Related Stocks

- [DRUG.AU - BetaShares Holdings Pty Ltd.](https://longbridge.com/zh-HK/quote/DRUG.AU.md)
- [MGNX.US - Macrogenics](https://longbridge.com/zh-HK/quote/MGNX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Launches Health Care Plan to Reduce Drug Costs | President Trump has launched "The Great Healthcare Plan" aimed at reducing prescription drug prices and insurance premiu | [Link](https://longbridge.com/zh-HK/news/272738903.md) |
| 13:31 ET
			
			
				The Journal of Clinical Pharmacology Celebrates 65 Years of Advancing Clinical Pharmacology | The Journal of Clinical Pharmacology (JCP) celebrates its 65th anniversary, highlighting its role in advancing clinical  | [Link](https://longbridge.com/zh-HK/news/272592270.md) |
| FDA prevails over EMA in 2025 novel drug approvals | In 2025, the FDA approved 46 new drugs, surpassing the EMA's 38 approvals. However, both agencies saw a decline in appro | [Link](https://longbridge.com/zh-HK/news/272953055.md) |
| FOCUS-Some drugmakers quietly concerned about legal risk with speedy FDA review program | Major drugmakers are participating in the FDA's expedited review program, but some are hesitant due to potential legal r | [Link](https://longbridge.com/zh-HK/news/272824482.md) |
| EXPLAINER-Hazards of ketamine in focus after actor Matthew Perry's 2023 overdose death | Actor Matthew Perry's 2023 death from a ketamine overdose has highlighted the drug's hazards. Originally used as an anes | [Link](https://longbridge.com/zh-HK/news/268406897.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。